Pacira Pharma (PCRX) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pacira Pharmaceuticals (PCRX) Data 'Increases Takeout Valuation' - Mizuho
March 1, 2017 10:30 AM ESTShares of Pacira Pharmaceuticals (NASDAQ: PCRX) are up 12% following positive Phase IV data from the TKA study. The study hit both of its co-primary endpoints (demonstrating statistically significant benefits for greater pain reduction (p=0.0381) and lower opioid utilization (p=0.0048). Secondary endpoints such as... More
